Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

April 19th 2023

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of two or greater.

AFM13 Exhibits Efficacy in CD30+ Relapsed/Refractory PTCL

April 17th 2023

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

FDA Places Partial Clinical Hold on Phase 1 Trial of MT-0169 in R/R Myeloma or Non-Hodgkin Lymphoma

April 11th 2023

The FDA has placed a partial clinical hold on a phase 1 trial investigating MT-0169 in patients with relapsed/refractory multiple myeloma or non-Hodgkin lymphoma.

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of select patients with large B-cell lymphoma who relapsed within 12 months from completion of or developed refractory disease to frontline chemoimmunotherapy.

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Investigators identified a set of microbiome-based biomarkers that may be used to optimize patient selection or increase personalization of treatment for patients with B-cell lymphoma receiving CAR T-cell therapy.

Dr. Bachanova on NK Cell Therapy in NHL

March 22nd 2023

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Axicabtagene ciloleucel produced a statistically significant improvement in overall survival compared with standard-of-caretherapy in patients with relapsed/refractory large B-cell lymphoma, according to data from the ZUMA-7 trial.

Dr. Wang on the Treatment Options for Unfit Patients With AML

March 21st 2023

Eunice Wang, MD, discusses treatment options in unfit patients with acute myeloid leukemia.

Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma

March 14th 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

The FDA has approved nelarabine for injection for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, according to an announcement from Shorla Oncology.

FDA Receives Type A Meeting Request for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

March 13th 2023

Soligenix has submitted a Type A meeting request to the FDA to discuss the contents of a refusal to file letter from the regulatory agency regarding the new drug application for synthetic hypericin for the treatment of early-stage cutaneous T-cell lymphoma.

FDA Panel Votes in Support of Favorable Benefit-Risk Profile for Polatuzumab Vedotin in Previously Untreated LBCL

March 9th 2023

The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 that data from the phase 3 POLARIX trial support a favorable benefit-risk profile for polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.

Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

February 20th 2023

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.

ADI-001 Produces Responses, Favorable Safety in Relapsed/Refractory B-Cell NHL

February 16th 2023

ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL

February 15th 2023

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Dr. Mukherjee on the Role of Disease Biology in the Treatment of MCL

February 14th 2023

Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13th 2023

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

CAR T-Cell Therapy for Patients With R/R FL

February 13th 2023

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

February 13th 2023

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

February 10th 2023

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).